MCID: PRS040
MIFTS: 88

Prostate Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer

MalaCards integrated aliases for Prostate Cancer:

Name: Prostate Cancer 54 38 12 24 25 71 29 13 52 41 3 14
Prostate Carcinoma 12 24 25 52 14 69
Prostate Cancer, Familial 54 12 50 69
Familial Prostate Cancer 50 56 29
Prostate Neoplasm 12 25 29
Prostate Cancer, Hereditary, 5 54 13
Prostate Cancer, Hereditary 54 50
Hereditary Prostate Cancer 12 50
Prostatic Neoplasms 42 69
Prostatic Neoplasm 12 25
Prostatic Cancer 12 25
Malignant Neoplasm of the Prostate 25
Prostate Cancer, Progression of 54
Malignant Tumor of the Prostate 12
Malignant Neoplasm of Prostate 69
Ngp - New Growth of Prostate 12
Malignant Tumor of Prostate 29
Prostate Cancer, Somatic 54
Prostate Cancer Somatic 54
Cancer of the Prostate 25
Tumor of the Prostate 12
Carcinoma of Prostate 12
Prostatic Carcinoma 25
Cancer of Prostate 12
Prostate Cancer 4 54
Prostate Cancer 3 54
Prca 71
Pc 71

Characteristics:

Orphanet epidemiological data:

56
familial prostate cancer
Prevalence: 1-9/100000 (United States); Age of onset: Adult;

OMIM:

54
Inheritance:
autosomal dominant form


HPO:

32
prostate cancer:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare urogenital diseases


External Ids:

OMIM 54 176807
Disease Ontology 12 DOID:10283 DOID:10286
ICD10 33 C61
ICD9CM 35 185
MeSH 42 D011471
Orphanet 56 ORPHA1331
MESH via Orphanet 43 C537243
UMLS via Orphanet 70 C2931456
ICD10 via Orphanet 34 C61
MedGen 40 C0376358
SNOMED-CT via HPO 65 263681008 399068003

Summaries for Prostate Cancer

MedlinePlus : 41 the prostate is the gland below a man's bladder that produces fluid for semen. prostate cancer is common among older men. it is rare in men younger than 40. risk factors for developing prostate cancer include being over 65 years of age, family history, and being african-american. symptoms of prostate cancer may include problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling low back pain pain with ejaculation to diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. you may also get a blood test for prostate-specific antigen (psa). these tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. if your results are abnormal, you may need more tests, such as an ultrasound, mri, or biopsy. treatment often depends on the stage of the cancer. how fast the cancer grows and how different it is from surrounding tissue helps determine the stage. men with prostate cancer have many treatment options. the treatment that's best for one man may not be best for another. the options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. you may have a combination of treatments. nih: national cancer institute

MalaCards based summary : Prostate Cancer, also known as prostate carcinoma, is related to prostate cancer 1 and prostate cancer, hereditary, 2, and has symptoms including angina pectoris, tremor and equilibration disorder. An important gene associated with Prostate Cancer is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are Prostate cancer and Endometrial cancer. The drugs Degarelix and Eligard have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lung, and related phenotypes are cellular and endocrine/exocrine gland

NIH Rare Diseases : 50 familialprostate cancer is a cluster of prostate cancer within a family. most cases of prostate cancer occur sporadically in people with no family history of the condition. however, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. in many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes (mutations) in the brca1, brca2, hoxb13, or several other genes. other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.high-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories. last updated: 12/7/2015

UniProtKB/Swiss-Prot : 71 Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

CDC : 3 Prostate cancer is the most common non-skin cancer among American men. Prostate cancers usually grow slowly. Most men with prostate cancer are older than 65 years and do not die from the disease. Finding and treating prostate cancer before symptoms occur may not improve your health or help you live longer.

Genetics Home Reference : 25 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.

Novus Biologicals : 53 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

Disease Ontology : 12 A male reproductive organ cancer that is located in the prostate.

Wikipedia : 72 Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system.... more...

Description from OMIM: 176807

Related Diseases for Prostate Cancer

Diseases in the Prostate Cancer family:

Prostate Cancer 1 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 13
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 7
Prostate Cancer, Hereditary, 2 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 9 Prostate Cancer, Hereditary, 15
Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 1 12.3
2 prostate cancer, hereditary, 2 12.2
3 prostate cancer, hereditary, 13 12.2
4 prostate cancer, hereditary, 11 12.2
5 prostate cancer, hereditary, 12 12.2
6 adenosquamous prostate carcinoma 12.1
7 prostate cancer susceptibility 12.0
8 medullomyoblastoma 11.8 AR CDH1 ELAC2 FOLH1 HOXB13 MSMB
9 prostate cancer, hereditary, 7 11.8
10 prostate cancer/brain cancer susceptibility, somatic 11.8
11 prostate cancer, progression and metastasis of 11.8
12 prostate cancer, hereditary, 10 11.8
13 prostate cancer, hereditary, 9 11.8
14 prostate cancer, hereditary, 15 11.8
15 prostate cancer, hereditary, 14 11.8
16 prostate cancer, hereditary, x-linked 2 11.8
17 prostate cancer, hereditary, x-linked 1 11.8
18 prostate carcinoma in situ 11.8
19 pulmonary fibrosis, idiopathic susceptibility 11.6 AR BRCA2 CDH1 CHEK2 ELAC2 HOXB13
20 bardet-biedl syndrome 11.6 AR BRCA2 CDH1 FOLH1 PTEN
21 prostatitis 11.5
22 splenic infarction 11.5 AR FOLH1 MSMB PTEN
23 infratentorial cancer 11.4 AR FOLH1 SRD5A2
24 brenner tumor of the vagina 11.4 BRCA2 CHEK2 PTEN
25 brenner tumor of ovary 11.4 BRCA2 CHEK2 PTEN
26 cellular myxoid liposarcoma 11.4 BRCA2 CHEK2 PTEN
27 childhood ovarian embryonal carcinoma 11.3 BRCA2 CHEK2 PTEN
28 nasopharyngeal carcinoma 11.3 BRCA2 CHEK2 PTEN
29 trachea squamous cell carcinoma 11.3 BRCA2 CDH1 PTEN
30 nail disorder, nonsyndromic congenital, 1 11.3 BRCA2 CDH1 PTEN
31 follicular basal cell carcinoma 11.2 AR CDH1
32 prostate disease 11.2
33 gastrojejunal ulcer 11.2 AR SRD5A2
34 radiation proctitis 11.1
35 bowman's membrane folds or rupture 11.1 AR PTEN
36 chest wall lymphoma 11.1 BRCA2 PTEN
37 pepck 1 deficiency 11.0 AR SRD5A2
38 vaginal discharge 10.9 AR SRD5A2
39 benign prostate phyllodes tumor 10.9
40 prostate neuroendocrine neoplasm 10.9
41 prostate malignant phyllodes tumor 10.9
42 diethylstilbestrol syndrome 10.8
43 prostate sarcoma 10.8
44 brca1 hereditary breast and ovarian cancer syndrome 10.8
45 brca2 hereditary breast and ovarian cancer syndrome 10.8
46 gastric cancer, somatic 10.8 CDH1 KLF6 ZFHX3
47 epilepsy, idiopathic generalized 11 10.7 AR SRD5A2
48 endotheliitis 10.5
49 hypoxia 10.4
50 insulin-like growth factor i 10.4

Comorbidity relations with Prostate Cancer via Phenotypic Disease Network (PDN): (show all 35)


Acute Kidney Failure Anthracosis
Asbestosis Azoospermia
Balanoposthitis Bladder Neck Obstruction
Chronic Kidney Failure Cystitis Cystica
Deficiency Anemia Disseminated Intravascular Coagulation
Epididymo-Orchitis Gout
Hydronephrosis Kidney Disease
Lipoma of Spermatic Cord Lymphadenitis
Nephrolithiasis, Type I Paralytic Ileus
Paraplegia Prostate Calculus
Prostate Carcinoma in Situ Prostate Disease
Prostatic Hypertrophy Prostatitis
Radiation Cystitis Spermatocele
Spinal Cord Disease Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Bladder Cancer Urinary Tract Obstruction
Y Chromosome Infertility

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to Prostate Cancer

Symptoms & Phenotypes for Prostate Cancer

Symptoms via clinical synopsis from OMIM:

54

Oncology:
early onset prostate cancer


Clinical features from OMIM:

176807

Human phenotypes related to Prostate Cancer:

32
id Description HPO Frequency HPO Source Accession
1 prostate cancer 32 HP:0012125

UMLS symptoms related to Prostate Cancer:


angina pectoris, tremor, equilibration disorder

MGI Mouse Phenotypes related to Prostate Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 EPHB2 FGFR4 HOXB13 KLF6 MAD1L1 MXI1
2 endocrine/exocrine gland MP:0005379 10.07 CDH1 CHEK2 EPHB2 HOXB13 KLF6 MSMB
3 mortality/aging MP:0010768 9.97 FGFR4 KLF6 MAD1L1 MSR1 MXI1 PTEN
4 neoplasm MP:0002006 9.7 AR BRCA2 CD82 CDH1 CHEK2 FGFR4
5 reproductive system MP:0005389 9.4 AR BRCA2 CDH1 EPHB2 FGFR4 HOXB13

Drugs & Therapeutics for Prostate Cancer

FDA approved drugs:

(show all 17)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Degarelix 17 46 degarelix Ferring Pharmaceuticals December of 2008
2
Eligard 17 46 LEUPROLIDE ACETATE Atrix Laboratories January 2002
3
Eulexin 17 FLUTAMIDE Schering-Plough June 1996
4
Iressa 17 46 GEFITINIB AstraZeneca May 2003
5
Jevtana 17 46 CABAZITAXEL sanofi aventis June 2010
6
Lupron Depot 17 46 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
7
Plenaxis 17 ABARELIX Praecis Pharmaceuticals December 2003
8
Provenge 17 46 sipuleucel-T Dendreon May 2010
9
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer May 1996
10
Trelstar Depot/ Trelstar LA 17 TRIPTORELIN PAMOATE Debio Rechereche Pharmaceutique, Target Research Associates/ Debiopharm June 2000/ June 2001
11
Viadur 17 46 LEUPROLIDE ACETATE Alza March 2000
12
Xgeva 17 46 DENOSUMAB Amgen June 2013/ November 2010
13
Xofigo 17 46 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
14
Xtandi 17 46 ENZALUTAMIDE Medivation August 2012
15
Zoladex 17 46 GOSERELIN ACETATE AstraZeneca January 1996
16
Zometa 17 46 ZOLEDRONIC ACID Novartis August 2001/ February 2002
17
Zytiga 17 46 ABIRATERONE ACETATE Centocor Ortho Biotech May 2011

Drugs for Prostate Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 871)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
2
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
3
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
4
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 164656-23-9 152945 6918296
5
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
6
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
8
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
10
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 56069 2375
11
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
12
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
13
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
14
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
15
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 71273 175805
16
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
17
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
18
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
19
Flutamide Approved Phase 4,Phase 3,Phase 2,Phase 1 13311-84-7 3397
20
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
21 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7681-49-4
22
Tamsulosin Approved, Investigational Phase 4,Phase 3 106133-20-4 129211
23
Finasteride Approved Phase 4,Phase 3,Phase 2 98319-26-7 57363
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
25
Diphenhydramine Approved Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
26
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
27
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
28
Ondansetron Approved Phase 4 99614-02-5 4595
29
Promethazine Approved Phase 4,Phase 2,Phase 1 60-87-7 4927
30
Ranitidine Approved Phase 4,Phase 2 66357-59-3, 66357-35-5 3001055
31
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
32
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
33
Desflurane Approved Phase 4 57041-67-5 42113
34
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
35
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
36
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
38
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
39
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
40
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
41
Hydromorphone Approved, Illicit Phase 4,Phase 3 466-99-9 5284570
42
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
43
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 9004-61-9 53477741 24759
44
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104987-11-3 445643 439492
45
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
46
Prilocaine Approved Phase 4 721-50-6 4906
47
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
48
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
49
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
50
Pamidronate Approved Phase 4,Phase 2 40391-99-9 4674

Interventional clinical trials:

(show top 50) (show all 3958)

id Name Status NCT ID Phase Drugs
1 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
2 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
3 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
4 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
5 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
6 Early Detection of Prostate Cancer by FACS Unknown status NCT00524823 Phase 4
7 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
8 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
9 Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
10 Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
11 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
12 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
13 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
14 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
15 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy Completed NCT00237146 Phase 4 Zoledronic acid
16 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
17 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
18 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
19 An Alternative to A Fixed Schedule In Management Of Prostate Cancer Completed NCT01056562 Phase 4
20 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed NCT01296672 Phase 4 Finasteride;Placebo
21 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
22 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
23 Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Completed NCT00805701 Phase 4 avodart;Placebo
24 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
25 Casodex/Zoladex Biomarkers in Localised Prostate Cancer Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
26 Docetaxel in the Treatment of Hormone Refractory Prostate Cancer Completed NCT00280098 Phase 4 docetaxel
27 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
28 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
29 Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Completed NCT00590213 Phase 4 Casodex 150mg
30 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
31 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
32 The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
33 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
34 Evaluate Recovery of Testosterone for Patients Using Eligard Completed NCT01136226 Phase 4 Eligard (TM)
35 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
36 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4 risedronate;placebo
37 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
38 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
39 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4 Zoledronic acid
40 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4 Zoledronic Acid
41 Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Completed NCT00953277 Phase 4
42 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
43 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
44 Local Anesthesia for Prostate Biopsy Completed NCT00422708 Phase 4
45 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
46 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide Completed NCT02149628 Phase 4 propofol;Desflurane
47 The Use of Thermal Suits as Preventing Hypothermia During Surgery Completed NCT01571544 Phase 4
48 The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function Completed NCT01547416 Phase 4 epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose;no epidural drug administered
49 Hydroxyethyl Starch and Renal Function After Radical Prostatectomy Completed NCT01486563 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9 mg/ml
50 Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? Completed NCT00982800 Phase 4 Gabapentin;Placebo Sugar Pill

Search NIH Clinical Center for Prostate Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Prostate Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Prostate Cancer:
Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers

Cochrane evidence based reviews: prostatic neoplasms

Genetic Tests for Prostate Cancer

Genetic tests related to Prostate Cancer:

id Genetic test Affiliating Genes
1 Malignant Tumor of Prostate 29
2 Familial Prostate Cancer 29
3 Prostate Cancer 29 24 RNASEL CHEK2
4 Prostate Neoplasm 29

Anatomical Context for Prostate Cancer

MalaCards organs/tissues related to Prostate Cancer:

39
Prostate, Bone, Lung, Lymph Node, Testes, Endothelial, T Cells

Publications for Prostate Cancer

Articles related to Prostate Cancer:

(show top 50) (show all 13255)
id Title Authors Year
1
Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell Motility. ( 28373430 )
2017
2
Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. ( 27410686 )
2017
3
MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer. ( 28350134 )
2017
4
Knockdown of FOXR2 suppresses the tumorigenesis, growth and metastasis of prostate cancer. ( 28068638 )
2017
5
MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. ( 27956179 )
2017
6
Effects of testosterone and 17I^a89estradiol on angiotensina89induced changes in tyrosine kinase activity in the androgena89independent human prostate cancer cell line, DU145. ( 28949385 )
2017
7
Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer. ( 28085790 )
2017
8
Health care costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated health care system. ( 28534659 )
2017
9
Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele. ( 28176139 )
2017
10
Androgen receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. ( 28091563 )
2017
11
Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer: A case-control study of Han Chinese men in Northeast China. ( 28272245 )
2017
12
Head-To-Head Comparison Between High- and Standard-b-Value DWI for Detecting Prostate Cancer: A Systematic Review and Meta-Analysis. ( 28952806 )
2017
13
Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERI+. ( 27696457 )
2017
14
Correction for Dash et al., Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. ( 28533399 )
2017
15
Association of estrogen receptor I+ PvuII and XbaI polymorphisms with prostate cancer susceptibility and risk stratification: a meta-analysis from case-control studies. ( 28721070 )
2017
16
Facial Paralysis and Hearing Loss: A Rare Manifestation of Prostate Cancer Metastases. ( 28409073 )
2017
17
Activation of GPR30 stimulates GTP-binding of GI+i1 protein to sustain activation of Erk1/2 in inhibition of prostate cancer cell growth and modulates metastatic properties. ( 27908592 )
2017
18
High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients. ( 27921521 )
2017
19
Repression of MicroRNA-372 by Arsenic Sulphide Inhibits Prostate Cancer Cell Proliferation and Migration through Regulation of large tumour suppressor kinase 2. ( 27730751 )
2017
20
BCL2A genotypes and prostate cancer survival. ( 28396899 )
2017
21
Elevated levels of autophagy-related marker ULK1 and mitochondrion-associated autophagy inhibitor LRPPRC are associated with biochemical progression and overall survival after androgen deprivation therapy in patients with metastatic prostate cancer. ( 27679555 )
2017
22
Malakoplakia of the Prostate as a Mimicker of Prostate Cancer on Prostate Health Index and Magnetic Resonance Imaging-Fusion Prostate Biopsy: A Case Report. ( 28736746 )
2017
23
PTTG1, A novel androgen responsive gene is required for androgen-induced prostate cancer cell growth and invasion. ( 27756608 )
2017
24
Effects of Caspase 9 Gene Polymorphism in Patients with Prostate Cancer. ( 28358701 )
2017
25
Repeatability of [(68)Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. ( 28534214 )
2017
26
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. ( 28614217 )
2017
27
miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. ( 28122308 )
2017
28
CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. ( 28130224 )
2017
29
Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. ( 28282546 )
2017
30
Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclinA D1 and MMP-7. ( 27922675 )
2017
31
Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer. ( 28631332 )
2017
32
c-Jun Contributes to Transcriptional Control of GNA12 Expression in Prostate Cancer Cells. ( 28394299 )
2017
33
Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating Engrailed-2. ( 27921232 )
2017
34
Active Surveillance of Prostate Cancer. ( 28090626 )
2017
35
Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer. ( 27815387 )
2017
36
miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells. ( 28384067 )
2017
37
Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro. ( 28008585 )
2017
38
Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-I_B transactivation in LNCaP cells. ( 28466782 )
2017
39
The ErbB family and androgen receptor signaling are targets ofA Celecoxib in prostate cancer. ( 28450158 )
2017
40
MNS16A tandem repeat minisatellite of human telomerase gene: functional studies in colorectal, lung and prostate cancer. ( 28427205 )
2017
41
Glycosylation is a global target for androgen control in prostate cancer cells. ( 28159857 )
2017
42
Upregulation of miR-146a by YY1 depletion correlates with delayed progression of prostate cancer. ( 28101571 )
2017
43
Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. ( 28004109 )
2017
44
Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. ( 27643404 )
2017
45
Aspirin Inhibits IKK-I^-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator. ( 28278500 )
2017
46
Reply to Thomas Zilli, Gilles Crehange and Olivier Chapet's Letter to the Editor re: Pascal Rischmann, Albert Gelet, Benjamin Riche, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol 2017;71:267-73. ( 28089305 )
2017
47
Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. ( 28533151 )
2017
48
SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation. ( 28417919 )
2017
49
Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans? ( 28795218 )
2017
50
Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. ( 27984115 )
2017